Recent Advances in Behavioral Psychopharmacology
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 15 December 2024 | Viewed by 192
Special Issue Editor
Interests: antidepressants; behavioral psychopharmacology; chronic stress; depression; ketamine; mGlu receptors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues，
The global burden of mental disorders continues to grow despite decades of detailed research in the field of neuroscience, using modern methods, including brain imaging techniques. Behavioral research using animal models of mental illnesses or screening tests used for finding potential drugs helps in the search for new forms of therapy. Animal models of mental disorders or at least some disease symptoms, although imperfect, also help to determine the pathomechanism of mental illnesses. Despite significant achievements in behavioral psychopharmacology, new efforts are still needed to cope with the growing problem of the spread of mental illness, and modern techniques appear to be essential in dealing with these challenges.
In this Special Issue, we would like to gather experts in behavioral psychopharmacology who focus on discovering new therapeutic agents and strategies and studying the mechanisms of changes in animal behavior in response to environmental fluctuations and pharmacological interventions. Original research articles and stimulating reviews that provide new interpretations of up-to-date results and the extant literature are highly welcome.
Dr. Agnieszka Pałucha-Poniewiera
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- addiction
- behavioral models
- behavioral pharmacology
- cognition
- depression
- drug abuse
- memory
- psychoactive drugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
